AusBiotech 2013 annual report shows year of solid delivery
The AusBiotech Annual Report 2013 has now been released, detailing another solid performance for AusBiotech and shows how it has delivered for its members and the Australian biotechnology industry. AusBiotech was steadfast in its advocacy and active in its representation and support of the industry, delivering a number of achievements in policy terms.
The period (July 1, 2012–June 30, 2013) was marked by the activation of the R&D Tax Incentive, which began returning vital cash flow to the sector, with at least A$45 million ($42.5 million) in cash refunds announced in media releases by biotechnology companies with turnover under A$20 million.
The leader board of ASX-listed biotech stocks continued their progress to market with clinical trials in Phase III, new product approvals, market launches, and now building sales for products, making partnership deals and acquisitions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze